Venezuela’s rival factions take power struggle to UN after talks fail

A round of negotiations brokered by Norway in recent months, aimed at peacefully resolving the crisis, has failed. (File/AFP)
Updated 19 September 2019

Venezuela’s rival factions take power struggle to UN after talks fail

  • Guaido is seeking to get more countries, especially the European Union, to implement sanctions on Venezuela
  • Maduro calls Guaido a US puppet seeking to oust him in a coup

CARACAS/WASHINGTON: Venezuela’s rival political factions will take their power struggle to New York next week, where representatives of President Nicolas Maduro and opposition chief Juan Guaido will each try to convince a gathering of world leaders at the United Nations that their boss is the country’s legitimate head of state.
The United States and more than 50 other countries recognize Guaido, the leader of the opposition-controlled National Assembly, as the rightful president. Guaido in January invoked the constitution to assume a rival presidency to Maduro, arguing the socialist president’s May 2018 re-election was a sham.
But the 193-member UN General Assembly still recognizes Maduro, who retains the support of the UN Security Council’s veto-wielding permanent members Russia and China, setting the stage for the two sides to air their public grievances as they battle for international backing.
A round of negotiations brokered by Norway in recent months, aimed at peacefully resolving the crisis, has failed.
Guaido is seeking to get more countries, especially the European Union, to implement sanctions on Venezuela, as the United States has done.
Maduro, who has overseen a collapse of the OPEC nation’s once-prosperous economy and has been accused by the UN’s High Commissioner for Human Rights of rights violations, wants to heap pressure on the United States to lift sanctions on state oil company PDVSA and members of his inner circle.
Critics say his government’s decisions this week to free a jailed opposition lawmaker and reform Venezuela’s electoral body, long accused of bias, were aimed at improving Maduro’s image before the UN gathering.
“They want to use the UN meeting to wash their face, because they are not reaching any real solutions for the Venezuelan people,” Carlos Valero, an opposition lawmaker who sits on the National Assembly’s foreign affairs committee, said in an interview on Wednesday.
Maduro calls Guaido a US puppet seeking to oust him in a coup, and blames Washington’s sanctions for Venezuela’s economic woes. Maduro himself said he will not attend the UN gathering, but he tasked two cabinet members with presenting a petition condemning the sanctions to Secretary General Antonio Guterres.
“The UN Secretary General and all the UN agencies should raise their voice to condemn the aggression Venezuela is being subjected to, to condemn the illegal blockade,” Foreign Minister Jorge Arreaza told reporters in Geneva last Friday. “We believe that a lot more can be done from the United Nations.”
’Until Maduro is gone’
Guaido has not yet decided whether he will attend, according to his US envoy Carlos Vecchio. Julio Borges, an exiled opposition lawmaker recently named Guaido’s chief diplomat, will be in New York for side events aimed at spotlighting Venezuela’s humanitarian crisis and Maduro’s alleged support for armed rebels in Colombia.
The events include a likely meeting of the signatories of the Rio Treaty, invoked earlier this month by a dozen members of the Organization of American States (OAS), including the United States. The treaty is a Cold War-era mutual defense pact that the countries said they had invoked in response to what they called Maduro’s threat to regional stability. The OAS, unlike the UN, recognizes Guaido as Venezuela’s rightful leader.
Maduro’s government denies supporting the Colombian rebels and says the Rio Treaty is a precursor to military intervention.
In April, US Vice President Mike Pence called on the UN to revoke the credentials of Maduro’s government and recognize Guaido, but Washington has taken no action to push the measure at the General Assembly. Diplomats said it was unlikely Washington would get the support needed.
Both Washington and Venezuela’s opposition are seeking to counter perceptions that their efforts to oust Maduro have stalled.
Though differences over Iran and Afghanistan policy were the main reasons for US President Donald Trump’s firing of his hawkish national security adviser John Bolton last week, Trump had also grown increasingly impatient with the failure of sanctions and diplomatic pressure to push Maduro from power.
Despite Trump’s vows that all options were on the table, he had resisted Bolton’s push for more military planning, according to a person familiar with the matter. Trump’s aides have made clear that he is likely to impose further sanctions but the economic weapons at Washington’s disposal appear to be dwindling.
US State Department spokeswoman Morgan Ortagus said in a statement on Tuesday that the United States continued to stand with Guaido and that sanctions “will not be lifted until Maduro is gone.”
“We look forward to coming together with regional partners to discuss the multilateral economic and political options we can employ to the threat to the security of the region that Maduro represents,” she said.


Indonesia begins human trials of anti-virus vaccine

Updated 34 min 30 sec ago

Indonesia begins human trials of anti-virus vaccine

  • The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday
  • The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines

JAKARTA: Indonesia is stepping up efforts to find a COVID-19 vaccine by launching human trials of a potentially effective drug amid criticism of its lacklustre handling of the pandemic and concerns about its plummeting economy.

The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday and is being conducted by the Padjadjaran University School of Medicine at six locations in Bandung, West Java province, where the university and the state-owned pharma company are based.

“The first day of the trial went well, with 20 volunteers in each of the six locations injected with the potential vaccine. We have no complaints so far, and we are preparing the second injection batch on Aug 14,” Iwan Setiawan, a spokesman for Bio Farma, told Arab News on Wednesday.

He added that the six-month trial would require the participation of 1,620 volunteers who were “in good health and had not tested positive” for the disease.

Ridwan Kamil, governor of West Java, Indonesia’s most populated province, is among the volunteers who have signed up for the trial.

The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines.

“The potential vaccine had gone through three trials; the pre-clinical, the clinical trial first phase and the second phase in China,” Bio Farma CEO Honesti Basyir said in a statement.

According to Basyir, Sinovac is one of the few institutions that have progressed to the third phase of the clinical trial from among hundreds of research institutions around the world that are developing the COVID-19 vaccine.

According to Oxford Business Group’s COVID-10 Economic Impact Assessment, there are more than 150 different vaccines that international researchers are working on. However, only 26 have reached the human trial stage so far.

Once the trials are concluded, Bio Farma will register the vaccine with the Food and Drug Supervisory Agency so that it can begin mass-production of the drug.

“We have prepared a production facility for the COVID-19 vaccine with a maximum capacity of 100 million dosages, and by the end of December this year we will have an increased production capacity to produce an additional 150 million dosages,” Basyir said.

President Joko Widodo oversaw the first injections to the batch of volunteers in one of the six locations and also toured Bio Farma’s production facility. 

“We hope this clinical trial would conclude in six months and so we can start producing the vaccine in January and vaccinate our people soon,” Widodo said.

State-Owned Enterprise Minister Erick Thohir, who is also the head of the COVID-19 mitigation and national economic recovery committee, said that Bio Farma was a well-established vaccine producer whose products were halal-compliant and used in 150 countries, including in the Middle East.

The collaboration with Sinovac is one of three vaccine-development projects that Indonesia is engaging in with foreign parties as it grapples with a surge in infections. At the same time, social restrictions and economic activities were eased. The other two projects are with South Korea’s Genexine and Norway’s Coalition for Epidemic, Preparedness and Innovation.

As of Wednesday, Indonesia had reported 130,718 infections with 1,942 new cases, 85,798 recoveries and 5,903 deaths, although experts suggest that the numbers could be higher due to the country’s low testing capacity.

Cases also surged in the capital Jakarta with workplaces emerging as the new infection clusters after thousands of employees returned to work recently.